A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients - FINE Trial
Makaleler > Tam Makale · 2017
Yazarlar: DEMIR Gulsen AKMAN, Recai TURKOGLU, Sabahattin SAIP, Ayşe Nur YÜCEYAR, Husnu EFENDI, Omer Faruk TURAN, Kadriye AGAN, Murat TERZI, Asli TUNCER, Belgin KOCER, Mithat KASAP, Zeynep CALISKAN, Group FINE STUDY
Noro Psikiyatri Arsivi, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2017, cilt 56, ss 253-257
Özet
INTRODUCTION: To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents. METHODS: Patients aged 18-65 years with RRMS who fulfilled the eligibility criteria were enrolled from 16 centers throughout Turkey. Treatment Satisfaction Questionnaire for Medication and 36-item Short-Form Health Survey were completed at baseline and four visits to assess patient satisfaction and quality of life. RESULTS: Forty-two patients (62% male; mean age: 35.7±9.4 years) were eligible for inclusion. Patient satisfaction scores at the end of the study (44.7±9.9) were significantly higher than those at baseline [32.0±9.9; (p<0.001)]. The only significant increase in the quality of life survey was in the emotional aspect (p=0.019). There were 124 adverse events and none of the five serious adverse events noted was considered drug-related. CONCLUSION: Large-scale comparative studies performed with disease specific quality of life instruments will allow more information on this issue.